Spectrum Pharmaceuticals Inc. (SPPI)

8.95
NASDAQ : Health Technology
Prev Close 9.45
Day Low/High 8.83 / 9.55
52 Wk Low/High 6.22 / 21.80
Avg Volume 752.60K
Exchange NASDAQ
Shares Outstanding 104.06M
Market Cap 983.32M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Spectrum Pharmaceuticals Commits To Review Shareholder Proposal

Spectrum Pharmaceuticals Commits To Review Shareholder Proposal

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today commented on the recent filing...

Spectrum Pharmaceuticals (SPPI) Is Today's Strong On High Volume Stock

Spectrum Pharmaceuticals (SPPI) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Spectrum Pharmaceuticals (SPPI) as a strong on high relative volume candidate

Spectrum Pharmaceuticals Reports Continued Advancement Of Robust, Late-Stage Pipeline And First Quarter 2015 Financial Results

Spectrum Pharmaceuticals Reports Continued Advancement Of Robust, Late-Stage Pipeline And First Quarter 2015 Financial Results

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results...

Spectrum Pharmaceuticals (SPPI) Is Strong On High Volume Today

Spectrum Pharmaceuticals (SPPI) Is Strong On High Volume Today

Trade-Ideas LLC identified Spectrum Pharmaceuticals (SPPI) as a strong on high relative volume candidate

Spectrum Pharmaceuticals Announces First Quarter 2015 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces First Quarter 2015 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a...

Spectrum Pharmaceuticals is Now Oversold (SPPI)

Spectrum Pharmaceuticals is Now Oversold (SPPI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Spectrum Pharmaceuticals Presents New Data On EVOMELATM (CE-Melphalan), At The Annual Meeting Of The American Pharmacists Association (APhA) In San Diego, Highlighting Stability

Spectrum Pharmaceuticals Presents New Data On EVOMELATM (CE-Melphalan), At The Annual Meeting Of The American Pharmacists Association (APhA) In San Diego, Highlighting Stability

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced results of a clinical...

Interesting SPPI Put And Call Options For November 20th

Interesting SPPI Put And Call Options For November 20th

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading this week, for the November 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Spectrum Pharmaceuticals Reports Robust Clinical Data And Strong 2014 Financial Results

Spectrum Pharmaceuticals Reports Robust Clinical Data And Strong 2014 Financial Results

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results...

Four Oncology Key Opinion Leaders To Present At Spectrum Pharmaceuticals' Analyst Day On Friday, March 13th

Four Oncology Key Opinion Leaders To Present At Spectrum Pharmaceuticals' Analyst Day On Friday, March 13th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, will be hosting its fourth quarter 2014...

Spectrum Pharmaceuticals Announces FDA's Acceptance Of NDA Filing For Captisol-Enabled™ (Propylene Glycol-Free) Melphalan

Spectrum Pharmaceuticals Announces FDA's Acceptance Of NDA Filing For Captisol-Enabled™ (Propylene Glycol-Free) Melphalan

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its New Drug...

Spectrum Pharmaceuticals In-Licenses Poziotinib, A Novel Pan-HER Inhibitor With Clinical Activity In Several Solid Tumors, From Hanmi Pharmaceuticals

Spectrum Pharmaceuticals In-Licenses Poziotinib, A Novel Pan-HER Inhibitor With Clinical Activity In Several Solid Tumors, From Hanmi Pharmaceuticals

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it has entered into a...

Spectrum Pharmaceuticals (SPPI) Stock Plunges to One-Year Low on Court's Fusilev Patent Ruling

Spectrum Pharmaceuticals (SPPI) Stock Plunges to One-Year Low on Court's Fusilev Patent Ruling

Shares of Spectrum Pharmaceuticals (SPPI) plummeted to a 52-week low on Monday after a U.S. District Court ruled Friday that patent claims of its Fusilev cancer drug are invalid.

Spectrum Pharmaceuticals To Present Corporate Update At The 2015 RBC Capital Markets' Global Healthcare Conference On February 24th

Spectrum Pharmaceuticals To Present Corporate Update At The 2015 RBC Capital Markets' Global Healthcare Conference On February 24th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the...

Spectrum Pharmaceuticals (SPPI) Shares Cross Above 200 DMA

Spectrum Pharmaceuticals (SPPI) Shares Cross Above 200 DMA

In trading on Thursday, shares of Spectrum Pharmaceuticals Inc crossed above their 200 day moving average of $7.55, changing hands as high as $7.67 per share. Spectrum Pharmaceuticals Inc shares are currently trading up about 4.4% on the day.

Spectrum Pharmaceuticals Announces Fourth Quarter 2014 Financial Results And Analyst Day

Spectrum Pharmaceuticals Announces Fourth Quarter 2014 Financial Results And Analyst Day

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will be hosting its...

Spectrum Pharmaceuticals Highlights Clinical Data For Captisol-Enabled™ (Propylene Glycol-Free) Melphalan At The 2015 BMT Tandem Meeting

Spectrum Pharmaceuticals Highlights Clinical Data For Captisol-Enabled™ (Propylene Glycol-Free) Melphalan At The 2015 BMT Tandem Meeting

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced results of a clinical...

First Week of SPPI March 20th Options Trading

First Week of SPPI March 20th Options Trading

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading this week, for the March 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new March 20th contracts and identified one put and one call contract of particular interest.

Spectrum Pharmaceuticals Files A New Drug Application With The FDA For Captisol-Enabled™ (Propylene Glycol-Free) Melphalan

Spectrum Pharmaceuticals Files A New Drug Application With The FDA For Captisol-Enabled™ (Propylene Glycol-Free) Melphalan

Spectrum Pharmaceuticals (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced the company has submitted a...

Spectrum Pharmaceuticals Highlights 11 Abstracts At The 56th Annual Meeting Of The American Society Of Hematology (ASH) In San Francisco, California, December 6-9, 2014

Spectrum Pharmaceuticals Highlights 11 Abstracts At The 56th Annual Meeting Of The American Society Of Hematology (ASH) In San Francisco, California, December 6-9, 2014

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced key presentations of...

Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind

Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2014 Global London Healthcare Conference On November 19th

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2014 Global London Healthcare Conference On November 19th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of...

Spectrum Pharmaceuticals Reports Strong Product Sales For The Third Quarter 2014; Sales Of $47.9 Million Up 15.6% Over Last Year

Spectrum Pharmaceuticals Reports Strong Product Sales For The Third Quarter 2014; Sales Of $47.9 Million Up 15.6% Over Last Year

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial ...

Spectrum Pharmaceuticals Announces Third Quarter 2014 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Third Quarter 2014 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a ...

SPPI Makes Notable Cross Below Critical Moving Average

SPPI Makes Notable Cross Below Critical Moving Average

In trading on Monday, shares of Spectrum Pharmaceuticals Inc crossed below their 200 day moving average of $7.98, changing hands as low as $7.87 per share. Spectrum Pharmaceuticals Inc shares are currently trading down about 3.3% on the day.

5 Breakout Stocks Under $10 Set to Soar Higher

5 Breakout Stocks Under $10 Set to Soar Higher

These stocks trading for less than $10 a share are within range of triggering breakout trades.

Spectrum Pharmaceuticals Out-Licenses Rights For Greater China To CASI Pharmaceuticals For Three Of Its Drugs

Spectrum Pharmaceuticals Out-Licenses Rights For Greater China To CASI Pharmaceuticals For Three Of Its Drugs

Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, and CASI Pharmaceuticals, Inc.

Spectrum Pharmaceuticals Announces Issue Of A New Patent For Beleodaq™ (belinostat) For Injection With Patent Term Adjustment Till 2027

Spectrum Pharmaceuticals Announces Issue Of A New Patent For Beleodaq™ (belinostat) For Injection With Patent Term Adjustment Till 2027

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the United...

5 Stocks Under $10 Soaring Higher

5 Stocks Under $10 Soaring Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Spectrum Pharmaceuticals Makes Decision To Advance SPI-2012, A Novel Long-Acting GCSF, To Phase 3 Due To Positive Phase 2 Results In Its Collaboration Program With Hanmi Pharm. Co.

Spectrum Pharmaceuticals Makes Decision To Advance SPI-2012, A Novel Long-Acting GCSF, To Phase 3 Due To Positive Phase 2 Results In Its Collaboration Program With Hanmi Pharm. Co.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced the Phase 3 Go/No-Go...

TheStreet Quant Rating: D (Sell)